Background Glasgow Prognostic Score (GPS) is a simple, systemic inflammation-based prognostic score used mostly in oncology and intensive-care.
Objectives We aimed to investigate the utility of GPS in assessing disease activity in patients with systemic lupus erythematosus (SLE).
Methods Patients admitted consecutively to our department were prospectively enrolled in the study. Clinical and biological parameters were assessed in each participant. Disease activity was quantified using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Systemic Lupus Activity Measure (SLAM) and European Consensus Lupus Activity Measurement (ECLAM). GPS was calculated using 1 point for C reactive protein>10mg/L and 1 point for hypoalbuminemia.
Results Our study group included 130 patients with a mean age of 46.58±12.69 years old and 90% female predominance, out of which 17 (13.07%) had a GPS≥1. Median ECLAM score was 2[0-7.5], median SLAM score was 4[0-24] and median SLEDAI score 6[0-48]. Patients with a GPS≥1 had a higher ECLAM score compared to those with a GPS=0 (3[0-10.5] vs. 2[0-7], p=0.007), a higher SLAM score (7[0-22] vs. 4[1-14], p=0.003), a higher SLEDAI score (8[0-48] vs. 4.5[0-30], p=0.006) and a higher erythrocyte sedimentation rate (ESR) (24[10-90] vs. 13.5[2-61], p=0.03). ROC curve analysis identified ECLAM and SLAM scores as predictors of a GPS≥1 with an AUC of 0.825 (95%CI 0.0.686-0.964, p=0.01) and 0.740 (95%CI 0.483-0.998, p=0.07) respectively. Elevated ESR was also associated with a GPS≥1 with an AUC of 0.819 (95%CI 0.693-0.945, p=0.01).
Conclusions GPS was correlated with disease activity in patients with SLE. A simple systemic inflammation score, it could be used as an auxiliary tool for their assessment.
Acknowledgements This paper is supported by POSDRU/159/1.5/S/137390.
Disclosure of Interest None declared